End-of-day quote
Shenzhen S.E.
06:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
40.09
CNY
|
-2.55%
|
|
-5.16%
|
+6.42%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
4,034
|
2,225
|
2,199
|
3,995
|
23,126
|
23,314
|
Enterprise Value (EV)
1 |
3,598
|
2,005
|
1,665
|
3,164
|
22,163
|
11,872
|
P/E ratio
|
-24.5
x
|
171
x
|
33.9
x
|
16.5
x
|
24.8
x
|
1.49
x
|
Yield
|
-
|
-
|
-
|
0.65%
|
1.41%
|
4.89%
|
Capitalization / Revenue
|
6.75
x
|
3.95
x
|
3.11
x
|
1.99
x
|
9.65
x
|
0.89
x
|
EV / Revenue
|
6.02
x
|
3.56
x
|
2.36
x
|
1.58
x
|
9.25
x
|
0.45
x
|
EV / EBITDA
|
-26.7
x
|
-18.4
x
|
-9.6
x
|
7
x
|
23.5
x
|
0.64
x
|
EV / FCF
|
-177
x
|
-3.89
x
|
-106
x
|
11.4
x
|
-5,198
x
|
1.03
x
|
FCF Yield
|
-0.56%
|
-25.7%
|
-0.95%
|
8.76%
|
-0.02%
|
97.3%
|
Price to Book
|
2.95
x
|
1.44
x
|
1.32
x
|
2.12
x
|
7.86
x
|
1.23
x
|
Nbr of stocks (in thousands)
|
432,806
|
432,806
|
432,806
|
432,806
|
466,729
|
456,157
|
Reference price
2 |
9.320
|
5.140
|
5.080
|
9.230
|
49.55
|
51.11
|
Announcement Date
|
4/26/18
|
4/29/19
|
6/28/20
|
4/27/21
|
4/29/22
|
4/28/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
597.9
|
563.9
|
706.3
|
2,008
|
2,397
|
26,315
|
EBITDA
1 |
-134.9
|
-109.1
|
-173.5
|
452.2
|
943.2
|
18,528
|
EBIT
1 |
-181.7
|
-132.7
|
-200.5
|
423.6
|
919.3
|
18,497
|
Operating Margin
|
-30.39%
|
-23.53%
|
-28.39%
|
21.09%
|
38.35%
|
70.29%
|
Earnings before Tax (EBT)
1 |
-157.5
|
-4.93
|
18.38
|
239.8
|
999.6
|
18,258
|
Net income
1 |
-165.9
|
12.69
|
66.45
|
242.3
|
908.6
|
16,030
|
Net margin
|
-27.74%
|
2.25%
|
9.41%
|
12.07%
|
37.91%
|
60.92%
|
EPS
2 |
-0.3800
|
0.0300
|
0.1500
|
0.5600
|
1.999
|
34.30
|
Free Cash Flow
1 |
-20.3
|
-516.1
|
-15.77
|
277.1
|
-4.264
|
11,552
|
FCF margin
|
-3.4%
|
-91.53%
|
-2.23%
|
13.8%
|
-0.18%
|
43.9%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
61.29%
|
-
|
62.35%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
114.37%
|
-
|
72.07%
|
Dividend per Share
|
-
|
-
|
-
|
0.0600
|
0.7000
|
2.500
|
Announcement Date
|
4/26/18
|
4/29/19
|
6/28/20
|
4/27/21
|
4/29/22
|
4/28/23
|
Fiscal Period: December |
2022 Q1
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
---|
Net sales
1 |
-
|
-
|
-
|
1,726
|
1,495
|
787.3
|
462.3
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
14,312
|
15,244
|
806.7
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
30.45
|
32.44
|
1.718
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/29/22
|
8/29/22
|
10/28/22
|
4/28/23
|
4/28/23
|
8/29/23
|
10/31/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
435
|
219
|
533
|
831
|
964
|
11,443
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-20.3
|
-516
|
-15.8
|
277
|
-4.26
|
11,552
|
ROE (net income / shareholders' equity)
|
-11.4%
|
-0.2%
|
1.73%
|
13.8%
|
40.1%
|
144%
|
ROA (Net income/ Total Assets)
|
-5.1%
|
-4.14%
|
-6.51%
|
12%
|
18%
|
90.1%
|
Assets
1 |
3,253
|
-306.5
|
-1,020
|
2,013
|
5,052
|
17,791
|
Book Value Per Share
2 |
3.160
|
3.560
|
3.840
|
4.350
|
6.300
|
41.50
|
Cash Flow per Share
2 |
1.510
|
1.010
|
0.7700
|
2.110
|
1.960
|
11.60
|
Capex
1 |
56.5
|
180
|
60.7
|
53.8
|
70.4
|
212
|
Capex / Sales
|
9.45%
|
31.87%
|
8.6%
|
2.68%
|
2.94%
|
0.81%
|
Announcement Date
|
4/26/18
|
4/29/19
|
6/28/20
|
4/27/21
|
4/29/22
|
4/28/23
|
|
1st Jan change
|
Capi.
|
---|
| +6.42% | 2.6B | | -1.89% | 12.56B | | -9.59% | 7.68B | | +21.82% | 5.18B | | -1.31% | 5.29B | | +0.02% | 4.57B | | -50.89% | 3.29B | | -10.02% | 2.2B | | -8.29% | 1.79B | | +1.72% | 1.76B |
Diagnostic & Testing Substances
|